相关实验视频
Updated: Nov 4, 2025

11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
38.6K
帕金森病中的神经保护:神秘,神话和误解
Anthony H V Schapira1, C Warren Olanow
1University Department of Clinical Neurosciences, Royal Free and University College Medical School, and Institute of Neurology, Queen Square, London, England. warren.olanow@mssm.edu
JAMA
|January 22, 2004
概括
为帕金森病 (PD) 寻找有效的神经保护疗法至关重要. 目前的治疗方法可以控制症状,但无法阻止疾病的进展,因此需要新的策略和可靠的临床试验终点.
科学领域:
- 神经退行性疾病研究
- 临床试验方法论 临床试验方法论
- 帕金森病治疗方法 帕金森病治疗方法
背景情况:
- 帕金森病在美国影响了100万,其特点是与年龄相关的神经退行.
- 现有的疗法可以控制症状,但长期使用会导致运动并发症和不受控制的痴呆症.
- 迫切需要神经保护疗法来减缓或逆转帕金森病的进展.
研究的目的:
- 审查研究帕金森病神经保护的临床试验.
- 解决解释试验结果中的争议,特别是关于终点的争议.
- 突出开发有效神经保护疗法的挑战.
主要方法:
- 对帕金森病神经保护现有临床试验的审查.
- 在帕金森病临床试验中对终点选择的分析.
- 讨论神经成像作为疾病进展的生物标志物.
主要成果:
- 许多药物在临床前研究中表现有前途,但在临床转化方面面临挑战.
- 选择由症状性药物效应无误的临床终点仍然很困难.
- 使用神经成像终点,但可能会受到药物效应的影响.
结论:
- 在帕金森病中解释神经保护试验是复杂的,因为终点挑战.
- 需要进一步的研究,以建立可靠的评估神经保护剂的方法.
- 开发能够减缓,阻止或逆转帕金森病进展的疗法是一个至关重要的未满足需求.
相关概念视频
Parkinson's Disease: Overview
1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
Parkinson's Disease: Treatment
623
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
623
Neural Regulation
40.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.8K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.3K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.3K
Alzheimer's Disease: Treatment
461
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
461
Alzheimer's Disease: Overview
952
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
952

